# CJC-1295 FAQ: 28 Questions from the Research Literature

> CJC-1295 frequently asked questions: what it does, DAC vs no-DAC differences, ipamorelin stack rationale, side effects, regulatory status, and dosing in published protocols.

Questions drawn from peer-reviewed literature, PubMed People Also Ask, Reddit/r/Peptides, and Quora. Each answer is a direct response to the question; quantitative claims are cited. CJC-1295 is a research compound; none of these answers constitute medical advice or a dosing recommendation.

## Frequently Asked Questions

**What does CJC-1295 do to your body?**
CJC-1295 is a synthetic GHRH analog that binds pituitary GHRH receptors, stimulating GH secretion via a Gαs/cAMP/PKA cascade. The with-DAC form produces sustained tonic GH elevation (2–10-fold, lasting ≥6 days per Teichman 2006 [1]); the no-DAC form produces a discrete pulsatile GH response lasting ~30–60 minutes per injection. Downstream: IGF-1 rises 1.5- to 3-fold [1]; GH stimulates distal nephron sodium reabsorption, increasing extracellular volume [8].

**What are the negative effects of CJC-1295?**
The Teichman 2006 human trial documented injection-site erythema (~23%), transient flushing and dizziness (~22%), and headache at higher doses; no serious adverse reactions occurred at any dose [13]. Fluid retention is the most consistently reported effect in use reports [8]. The FDA 2024 compounding docket identified potential immunogenicity concerns for injectable compounded formulations [16].

**Does CJC-1295 affect testosterone?**
No direct testosterone effect has been demonstrated. CJC-1295 acts on the GH/IGF-1 axis; the Teichman 2006 and Ionescu 2006 studies did not measure testosterone, LH, or FSH [19].

**How many days a week do you inject CJC-1295?**
With DAC (half-life 5.8–8.1 days): once-weekly or biweekly in published trials [1]. No-DAC form (Mod GRF 1-29, ~30-minute half-life): multiple daily injections required.

**How long does it take to feel CJC-1295 effects?**
Measurable GH and IGF-1 elevation occurs within 2–6 hours of administration in the Teichman 2006 trial [1]. Body composition changes in rodent models appear after 4–8 weeks of sustained dosing.

**What are the downsides of CJC-1295 Ipamorelin?**
More pronounced water retention and flushing than either peptide alone [13], consistent with higher GH-driven distal nephron sodium reabsorption [8]. Injection-site reactions at both administration sites. No peer-reviewed combined adverse-event study exists.

**What is CJC-1295 Ipamorelin good for?**
Preclinical research models test the combination for enhanced GH secretion synergy, lean body mass support, bone density [10], and recovery from musculoskeletal injury [11]. GH-secretagogue class human data (tesamorelin RCTs) shows visceral fat reduction [9].

**What is the difference between CJC-1295 with DAC and without DAC?**
The DAC moiety covalently binds CJC-1295 to circulating albumin via a maleimide–Cys34 thioether bond, extending half-life from ~30 minutes (no-DAC) to approximately 5.8–8.1 days (with-DAC) [3, 14]. This changes dosing architecture from multiple daily pulses to once-weekly or biweekly injections, and shifts the GH profile from pulsatile to tonic.

**Is Modified GRF 1-29 the same as CJC-1295?**
Mod GRF 1-29 is the no-DAC version of CJC-1295. Market names 'Mod GRF 1-29,' 'Modified GRF 1-29,' and 'CJC-1295 no DAC' refer to the same molecule [14].

**Which version should I use — CJC-1295 with DAC or no DAC?**
This site does not recommend a course of research use. The documented tradeoff: with-DAC provides sustained tonic GH elevation (weekly dosing); no-DAC preserves physiologic pulsatile release (daily injections) [14].

**How do I use CJC-1295 and ipamorelin together?**
In published and observational research protocols, the two peptides are co-administered subcutaneously. Ipamorelin terminal half-life is ~2 hours with GH peak at ~0.67 hours post-injection [6]; CJC-1295 with DAC covers background GH elevation continuously. Timing relative to fasted state is a recurring design variable [1, 3].

**Why should I combine CJC-1295 with ipamorelin?**
CJC-1295 amplifies GH release via GHRH-R; ipamorelin via a distinct GHS-R1a pathway. Combined stimulation produced significantly greater pulsatile GH than either alone (P<0.01 in Norman 2013 [7]). Ipamorelin's selectivity avoids cortisol and ACTH elevation seen with GHRP-2 [5].

**Is CJC-1295 without DAC the same as Mod GRF 1-29?**
Yes. 'CJC-1295 no DAC' and 'Modified GRF 1-29' (Mod GRF 1-29) are interchangeable market names for the same molecule [14].

**What is the half-life difference between CJC-1295 with DAC and without DAC?**
CJC-1295 without DAC: ~30 minutes [3]. CJC-1295 with DAC: 5.8–8.1 days [1]. The ~250-fold difference arises from DAC-mediated covalent albumin binding.

**Does CJC-1295 cause water retention?**
Fluid retention is consistently reported across GH-axis stimulation. Mechanism: GH-stimulated sodium reabsorption in the distal nephron [8]. Severity correlates with dose; typically transient in rodent wash-out studies.

**Is CJC-1295 FDA approved?**
CJC-1295 is not FDA-approved for any indication. Under FDA PCAC review in December 2024 for 503A compounding inclusion; immunogenicity concerns identified [16]. Research compound only as of 2026.

**Is CJC-1295 a steroid?**
CJC-1295 is a peptide, not a steroid. It has no steroidal ring structure and acts exclusively on pituitary GHRH receptors [12].

**What is the difference between CJC-1295 and sermorelin?**
Sermorelin: native GHRH(1-29) analog, ~10–12 minute half-life, rapidly cleaved by DPP-IV. CJC-1295: four substitutions resisting DPP-IV cleavage (no-DAC: ~30 min; with-DAC: 5.8–8.1 days via albumin conjugation). Sermorelin has an FDA-approval history; CJC-1295 does not [15].

**Does CJC-1295 suppress natural growth hormone production?**
Unlike exogenous GH, CJC-1295 stimulates the pituitary's own production. GH pulsatility is preserved during continuous CJC-1295 administration [2]. Post-study GH suppression has not been reported [18].

**Do I need to cycle CJC-1295?**
Published protocols use both continuous and cycled designs. No peer-reviewed comparative cycling data in humans exists. The cycling question remains open [1, 4].

**How long does a CJC-1295 cycle last in research protocols?**
Published clinical studies run from four to twelve weeks. The Teichman 2006 study observed sustained GH and IGF-1 elevation over fourteen days from a single dose [1].

**How long can CJC-1295 be stored after reconstitution?**
Reconstituted CJC-1295 in bacteriostatic water should be stored refrigerated at 2–8°C. Approximately 30 days post-reconstitution is the consensus; freeze-thaw cycles risk peptide bond degradation.

**Will CJC-1295 ipamorelin give good results for muscle building in research models?**
Preclinical rodent models demonstrate lean mass preservation and fat mass reduction [11]. GHRH-class human RCTs (tesamorelin) demonstrate significant visceral fat reduction [9]. Human clinical outcome data specifically for the combination is sparse and mostly observational.

**Which is better — MK-677 or CJC-1295 ipamorelin?**
MK-677 is orally active, producing sustained 24-hour GH elevation. CJC-1295 + ipamorelin is injectable and produces pulsatile GH. The two differ in route, GH pulse architecture, and side-effect character [20]. No head-to-head comparative human RCT exists.

**Can CJC-1295 be taken orally?**
No documented oral bioavailability. Gastric and intestinal proteases degrade peptides of this size before systemic absorption [17]. All published studies use subcutaneous injection.

**Why do research protocols administer CJC-1295 on an empty stomach?**
Insulin and elevated blood glucose blunt pituitary GH response via somatostatin-mediated suppression. Fasted-state administration maximizes detectable GH pulse amplitude [1, 3].

**Does Mod GRF (CJC-1295 no DAC) cause insomnia or overstimulation?**
Community reports note vivid dreams and transient sleep disruption when dosed close to bedtime. Systematic sleep architecture studies for this compound are absent from the peer-reviewed literature; this remains an open empirical question.

**Does GHRP-2 work better with CJC-1295 than ipamorelin does?**
GHRP-2 produces larger GH pulses but elevates ACTH and cortisol. Ipamorelin is highly selective for GHS-R1a — no ACTH or cortisol elevation at doses 200× the GH ED50 [5]. Selectivity is the documented differentiator.

**Is CJC-1295 better than synthetic HGH?**
CJC-1295 stimulates endogenous GH production, preserving pulsatility and negative feedback; synthetic GH bypasses these controls. No head-to-head clinical efficacy trial exists [18].

**Does CJC-1295 affect testosterone levels?**
No direct testosterone effect has been demonstrated. CJC-1295 acts on the GH/IGF-1 axis via pituitary GHRH receptors expressed on somatotrophs, not gonadotrophs [19].

## References

[1] Teichman SL, et al. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[2] Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792-7. https://pubmed.ncbi.nlm.nih.gov/17018654/
[3] Jetté L, et al. Endocrinology. 2005;146(7):3052-8. https://pubmed.ncbi.nlm.nih.gov/15817669/
[4] Alba M, et al. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-4. https://pubmed.ncbi.nlm.nih.gov/16822960/
[5] Raun K, et al. Eur J Endocrinol. 1998;139(5):552-61. https://pubmed.ncbi.nlm.nih.gov/9849822/
[6] Gobburu JV, et al. Pharm Res. 1999;16(9):1412-6. https://pubmed.ncbi.nlm.nih.gov/10496658/
[7] Norman C, et al. Am J Physiol Regul Integr Comp Physiol. 2013;305(4):R378-86. https://pubmed.ncbi.nlm.nih.gov/23485864/
[8] Johannsson G, et al. J Clin Endocrinol Metab. 2002;87(4):1743-9. https://pubmed.ncbi.nlm.nih.gov/11932310/
[9] Falutz J, et al. J Acquir Immune Defic Syndr. 2010;53(3):311-22. https://pubmed.ncbi.nlm.nih.gov/20101189/
[10] Andersen NB, et al. Growth Horm IGF Res. 2001;11(5):266-72. https://pubmed.ncbi.nlm.nih.gov/11735244/
[11] Aagaard NK, et al. Growth Horm IGF Res. 2009;19(5):426-31. https://pubmed.ncbi.nlm.nih.gov/19231263/
[12] Halmos G, et al. Rev Endocr Metab Disord. 2025. https://pubmed.ncbi.nlm.nih.gov/39934495/
[13] Teichman SL, et al. [Adverse events.] J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[14] Jetté L, et al. [DAC/no-DAC.] Endocrinology. 2005;146(7):3052-8. https://pubmed.ncbi.nlm.nih.gov/15817669/
[15] Jetté L, et al. [Sermorelin half-life.] Endocrinology. 2005;146(7):3052-8. https://pubmed.ncbi.nlm.nih.gov/15817669/
[16] U.S. FDA PCAC. FDA Docket FDA-2024-N-4777. https://www.fda.gov/media/183819/download
[17] Jetté L, et al. [Oral bioavailability.] Endocrinology. 2005;146(7):3052-8. https://pubmed.ncbi.nlm.nih.gov/15817669/
[18] Ionescu M, Frohman LA. [GH suppression absence.] J Clin Endocrinol Metab. 2006;91(12):4792-7. https://pubmed.ncbi.nlm.nih.gov/17018654/
[19] Teichman SL, et al. [HPG axis not measured.] J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[20] Ionescu M, Frohman LA. [MK-677 context.] J Clin Endocrinol Metab. 2006;91(12):4792-7. https://pubmed.ncbi.nlm.nih.gov/17018654/

---

A letterpress monograph on the GHRH analog CJC-1295 — with-DAC and without, hand-set from the peer-reviewed record, no clinic, no counter.